- Home
- VRTX vs APP Comparison
VRTX vs APP Comparison
Compare VRTX & APP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRTX
- APP
- Stock Information
- Founded
- VRTX 1989
- APP 2012
- Country
- VRTX United States
- APP United States
- Employees
- VRTX N/A
- APP N/A
- Industry
- VRTX EDP Services
- APP EDP Services
- Sector
- VRTX Technology
- APP Technology
- Exchange
- VRTX Nasdaq
- APP Nasdaq
- Market Cap
- VRTX 104.8B
- APP 116.4B
- IPO Year
- VRTX 1991
- APP 2021
- Fundamental
- Price
- VRTX $422.00
- APP $342.34
- Analyst Decision
- VRTX Buy
- APP Buy
- Analyst Count
- VRTX 30
- APP 20
- Target Price
- VRTX $503.92
- APP $304.89
- AVG Volume (30 Days)
- VRTX 2.1M
- APP 4.0M
- Earning Date
- VRTX 02-03-2025
- APP 02-12-2025
- Dividend Yield
- VRTX N/A
- APP N/A
- EPS Growth
- VRTX N/A
- APP 1098.41
- EPS
- VRTX N/A
- APP 3.31
- Revenue
- VRTX $10,625,800,000.00
- APP $4,289,729,999.00
- Revenue This Year
- VRTX $12.56
- APP $41.33
- Revenue Next Year
- VRTX $8.34
- APP $22.48
- P/E Ratio
- VRTX N/A
- APP $103.48
- Revenue Growth
- VRTX 10.06
- APP 41.48
- 52 Week Low
- VRTX $377.85
- APP $40.71
- 52 Week High
- VRTX $519.88
- APP $417.64
- Technical
- Relative Strength Index (RSI)
- VRTX 48.34
- APP 55.37
- Support Level
- VRTX $397.25
- APP $307.07
- Resistance Level
- VRTX $425.49
- APP $362.45
- Average True Range (ATR)
- VRTX 8.24
- APP 16.82
- MACD
- VRTX 3.71
- APP -2.16
- Stochastic Oscillator
- VRTX 79.84
- APP 63.69
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
About APP Applovin Corporation
AppLovin Corp is a mobile app technology company. It focuses on growing the mobile app ecosystem by enabling the success of mobile app developers. The company's software solutions provide tools for mobile app developers to grow their businesses by automating and optimizing the marketing and monetization of their applications.